Now, researchers are exploring another surprising benefit its potential to reduce alcohol consumption
Risk factors that may prompt additional consideration include: Active gastrointestinal symptoms (nausea, vomiting, abdominal pain) Recent dose increases or being in the dose-escalation phase Higher doses of semaglutide Known gastroparesis or other conditions affecting gastric emptying Obesity with GERD or hiatal hernia Based on the 2024 multi-society guidance, most patients can continue GLP-1 receptor agonists before elective procedures with appropriate risk assessment and mitigation strategies, rather than automatic postponement
The study design included two rounds of a three-day vehicle-treated baseline phase, a three-day treatment phase, and a two-to-three-day washout phase
Focus on lean protein sources like chicken, fish, tofu, and legumes to maintain muscle while losing weight
Such medications should be held for a sufficient amount of time before performing GI motility studies, for both therapeutic and diagnostic purposes